RESUMEN
Aggregatibacter actinomycetemcomitans (Aa), a Gram-negative coccobacillus commonly associated with endocarditis, poses a rare diagnostic challenge in pediatric cases. The presentation of two pediatric cases-myositis and chest mass-highlights novel aspects, including unusual symptom presentations in children which can be mistaken for malignancy. The limited sensitivity of standard blood tests complicates diagnosis, leading to delayed diagnosis and treatment. Representative samples must be taken, especially if blood cultures are negative. Despite advances in detection methods, diagnosing Aa infection remains difficult due to its rarity in children and variable clinical presentation. In conclusion, a comprehensive understanding of Aa infection in children is essential for early and effective diagnostic and therapeutic management.
Asunto(s)
Aggregatibacter actinomycetemcomitans , Infecciones por Pasteurellaceae , Humanos , Aggregatibacter actinomycetemcomitans/aislamiento & purificación , Masculino , Infecciones por Pasteurellaceae/diagnóstico , Infecciones por Pasteurellaceae/microbiología , Femenino , Niño , Miositis/microbiología , Miositis/diagnóstico , Antibacterianos/uso terapéutico , PreescolarRESUMEN
BACKGROUND: Pneumococcal serotypes 1, 3, 5, 7F, and 19A were the most implicated in community-acquired pneumonia (CAP) after implementation of 7-valent pneumococcal conjugate vaccine (PCV7). In France, the switch from PCV7 to 13-valent pneumococcal conjugate vaccine (PCV13) occurred in June 2010. An active surveillance network was set up to analyze the impact of PCV13 on CAP. METHODS: An observational prospective study performed in 8 pediatric emergency departments from June 2009 to May 2012 included all children between 1 month and 15 years of age with chest radiography-confirmed pneumonia. Three 1-year periods were defined: pre-PCV13, transitional, and post-PCV13. RESULTS: During the 3-year study period, among the 953 274 pediatric emergency visits, 5645 children with CAP were included. CAP with pleural effusion and documented pneumococcal CAP were diagnosed in 365 and 136 patients, respectively. Despite an increase (4.5%) in number of pediatric emergency visits, cases of CAP decreased by 16% (2060 to 1725) between pre- and post-PCV13 periods. The decrease reached 32% in infants in the same periods (757 to 516; P < .001). Between pre- and post-PCV13 periods, the proportion of CAP patients with a C-reactive protein level >120 mg/dL decreased from 41.3% to 29.7% (P < .001), the number of pleural effusion cases decreased by 53% (167 to 79; P < .001) and the number of pneumococcal CAP cases decreased by 63% (64 to 24; P = .002). The number of additional PCV13 serotypes identified decreased by 74% (27 to 7). CONCLUSIONS: Our data suggest a strong impact of PCV13 on CAP, pleural effusion, and documented pneumococcal pneumonia, particularly cases due to PCV13 serotypes.
Asunto(s)
Infecciones Comunitarias Adquiridas/prevención & control , Vacunas Neumococicas/uso terapéutico , Neumonía Neumocócica/prevención & control , Proteína C-Reactiva , Niño , Preescolar , Infecciones Comunitarias Adquiridas/epidemiología , Francia/epidemiología , Humanos , Lactante , Masculino , Neumonía Neumocócica/epidemiología , Estudios Prospectivos , Vacunas Conjugadas/uso terapéuticoRESUMEN
The French infectious diseases (ID) program was accessible to all medical trainees enrolled in postgraduate training for other specialties until 2017, when it became an independent specialty. Therefore, the national ID training is no longer accessible to pediatricians, and a specific program for pediatric ID (PID) is under development. We conducted a survey among French pediatric trainees enrolled in the former ID training to assess their satisfaction and describe the barriers they may have faced during the training. A questionnaire was sent in October 2018 to all pediatricians enrolled in this curriculum. Among the 17 trainees who replied, almost half (8/17) described the ID training as being hardly accessible to pediatricians, and six reported difficulties in finding a mandatory one-year position in an ID department to complete their training. Future training in PID should address these issues.
Asunto(s)
Enfermedades Transmisibles , Pediatras/educación , Actitud del Personal de Salud , Niño , Enfermedades Transmisibles/diagnóstico , Enfermedades Transmisibles/terapia , Curriculum , Francia , Humanos , Encuestas y CuestionariosRESUMEN
OBJECTIVES: To determine the predictors of a positive SARS-CoV-2 test in a pediatric ambulatory setting. PATIENTS AND METHODS: We performed a cross-sectional prospective study (November 2020-February 2022) of 93 ambulatory settings in France. We included symptomatic children < 15 years old tested for SARS-CoV-2. For each period corresponding to the spread of the original strain and its variants (period 1: original strain; period 2: Alpha, period 3: Delta; period 4: Omicron), we used a multivariate analysis to estimate adjusted odds ratios (aORs) associated with COVID-19 among age, signs, symptoms or contact, and 95 % confidence intervals (95CIs). RESULTS: Of 5,336 children, 13.9 % (95CI 13.0-14.8) had a positive test. During the first three periods, the positivity rate ranged from 5.6 % (95CI 4.6-6.7) to 12.6 % (95CI 10.8-14.6). The main factors associated with a positive test were contact with an infected adult at home or outside the home (aOR 11.5 [95CI 4.9-26.9] to 38.9 [95CI 19.3-78.7]) or an infected household child (aOR 15.0 [95CI 4.8-47.1] to 28.4 [95CI 8.7-92.6]). By contrast, during period 4, aORs for these predictors were substantially lower (2.3 [95CI 1.1-4.5] to 5.5 [95CI 3.2-7.7]), but the positivity rate was 45.7 % (95CI 42.3-49.2). CONCLUSIONS: In pediatric ambulatory settings, before the Omicron period, the main predictor of a positive test was contact with an infected person. During the Omicron period, the odds of these predictors were substantially lower while the positivity rate was higher. An accurate diagnostic strategy should only rely on testing and not on age, signs, symptoms or contact.
Asunto(s)
COVID-19 , SARS-CoV-2 , Adulto , Humanos , Niño , Adolescente , COVID-19/diagnóstico , COVID-19/epidemiología , Estudios Transversales , Estudios ProspectivosRESUMEN
NALP proteins, also known as NLRPs, belong to the CATERPILLER protein family involved, like Toll-like receptors, in the recognition of microbial molecules and the subsequent activation of inflammatory and immune responses. Current advances in the function of NALPs support the recently proposed model of a disease continuum bridging autoimmune and autoinflammatory disorders. Among these diseases, hereditary periodic fevers (HPFs) are Mendelian disorders associated with sequence variations in very few genes; these variations are mostly missense mutations whose deleterious effect, which is particularly difficult to assess, is often questionable. The growing number of identified sporadic cases of periodic fever syndrome, together with the lack of discriminatory clinical criteria, has greatly hampered the identification of new disease-causing genes, a step that is, however, essential for appropriate management of these disorders. Using a candidate gene approach, we identified nonambiguous mutations in NALP12 (i.e., nonsense and splice site) in two families with periodic fever syndromes. As shown by means of functional studies, these two NALP12 mutations have a deleterious effect on NF-kappaB signaling. Overall, these data identify a group of HPFs defined by molecular defects in NALP12, opening up new ways to manage these disorders. The identification of these first NALP12 mutations in patients with autoinflammatory disorder also clearly demonstrates the crucial role of NALP12 in inflammatory signaling pathways, thereby assigning a precise function to this particular member of an emerging family of proteins whose putative biological properties are currently inferred essentially through in vitro means.
Asunto(s)
Fiebre Mediterránea Familiar/genética , Péptidos y Proteínas de Señalización Intracelular/genética , Secuencia de Aminoácidos , Secuencia de Bases , Niño , Codón sin Sentido/genética , Femenino , Humanos , Péptidos y Proteínas de Señalización Intracelular/fisiología , Masculino , Datos de Secuencia Molecular , Mutación , FN-kappa B/metabolismo , Linaje , Sitios de Empalme de ARN , Empalme del ARN/genética , Análisis de Secuencia de ADNRESUMEN
BACKGROUND: Urinary tract infections (UTIs) are a common source of bacterial infections in childhood. Making a proper diagnosis is important but requires invasive urine collection techniques. We aimed to derive a clinical decision rule to identify non-toilet-trained febrile girls at high risk for UTIs to restrict urethral catheterizations (UCs) to this high-risk group of patients. METHODS: We included all non-toilet-trained girls with a positive microscopic urinalysis from urine collected by sterile bag in a prospective cohort study to derive a model to predict UTI assessed by urine culture from UC. RESULTS: Thirty-seven patients were included. Absence of another source of fever on examination and the child's unusual behaviour were found to be independent predictors of UTI. The corresponding model offered an 85% sensitivity [95% confidence interval (CI): 56-96], with a 59% specificity (95% CI: 30-83) for UTI. The internal cross-validation by bootstrap led to an 85% sensitivity (95% CI: 68-100), and a 59% specificity (95% CI: 35-83). CONCLUSION: We derived a clinical decision model to selectively identify young febrile girls at high risk for UTI with a positive microscopic analysis and propose UC with an 85% sensitivity, which would avoid approximately 60% of unnecessary UCs; although further validation is necessary before daily clinical use.
Asunto(s)
Fiebre/etiología , Cateterismo Urinario , Infecciones Urinarias/diagnóstico , Preescolar , Infecciones por Escherichia coli/complicaciones , Infecciones por Escherichia coli/diagnóstico , Femenino , Humanos , Lactante , Recién Nacido , Infecciones por Klebsiella/complicaciones , Infecciones por Klebsiella/diagnóstico , Klebsiella pneumoniae/aislamiento & purificación , Estudios Prospectivos , Infecciones por Proteus/complicaciones , Infecciones por Proteus/diagnóstico , Proteus mirabilis/aislamiento & purificación , Reproducibilidad de los Resultados , Sensibilidad y Especificidad , Procedimientos Innecesarios , Infecciones Urinarias/complicaciones , Orina/microbiologíaRESUMEN
We report the case of a 13-month-old infant who was referred to the pediatric emergency department because of psychomotor regression with four bone fractures due to nutritional rickets. The reason was prolonged breastfeeding from a vegetarian mother followed by a vegan diet for the infant after weaning. Rickets is one of the many nutritional deficiencies that could affect infants fed vegan or vegetarian diets. These diets are a public health concern requiring adapted information that suggests alternative formulas made from rice or soy proteins and adapted supplementation after weaning.
Asunto(s)
Dieta Vegana/efectos adversos , Raquitismo/diagnóstico , Lactancia Materna , Dieta Vegetariana/efectos adversos , Humanos , Lactante , Masculino , Raquitismo/etiología , DesteteRESUMEN
The objective of this study was to determine the number of cases of pediatric meningitis or purpura fulminans associated with an incorrect vaccination status from 2011 to 2013 in France. A total of 48 children with vaccine-preventable meningitis or purpura fulminans, including three deaths, had an incorrect vaccination status: 26 cases were due to Neisseria meningitidis group C (54.2%), 19 to Streptococcus pneumoniae (39.6%), and three to Haemophilus influenzae type b (6.3%). The majority of patients (n=35, 72.9%) had received no injection of the vaccine concerned. Over a 3-year period, 48 cases of bacterial meningitis or purpura fulminans in children could have been avoided if the French immunization schedule had been followed.
Asunto(s)
Esquemas de Inmunización , Meningitis Bacterianas/epidemiología , Vacunación/estadística & datos numéricos , Enfermedades Prevenibles por Vacunación/epidemiología , Adolescente , Vacunas Bacterianas , Niño , Preescolar , Femenino , Francia/epidemiología , Vacunas contra Haemophilus , Haemophilus influenzae tipo b , Humanos , Lactante , Masculino , Neisseria meningitidis , Estudios Prospectivos , Púrpura Fulminante/epidemiología , Streptococcus pneumoniaeRESUMEN
Kawasaki disease is a form of idiopathic systemic vasculitis. Diagnosis is based upon specific clinical parameters. Cardiac manifestations explain the mortality rate. They can be reduced by early treatment using intravenous immunoglobulin. Atypical Kawasaki disease is difficult to diagnose and can delay diagnosis. We report a case of Kawasaki disease with arthritis in a 4-year-old girl whose initial presentation was a febrile torticollis. A literature review details the atypical early signs of Kawasaki disease revealed by torticollis.
Asunto(s)
Fiebre/etiología , Síndrome Mucocutáneo Linfonodular/diagnóstico , Tortícolis/etiología , Preescolar , Femenino , HumanosRESUMEN
The use of dexamethasone (DXM) as adjunctive therapy for bacterial meningitis (BM) in infants and children has remained controversial for 20 years. In spite of solid pathophysiological arguments, the limited number of patients, methodological flaws in clinical studies taken individually and pooled into meta-analyses, and the emergence of pneumococcal cephalosporin-resistance did not allow to reach a consensus on the effectiveness of DXM in the prevention of neurological sequelae, in the course of non Haemophilus influenzae b (Hib) BM. A recent meta-analysis conducted with an adequate number of patients (2,750 patients including 2,074 infants and children below 15 years of age) demonstrated that DXM prevented mortality and sequelae in adults with pneumococcal meningitis and suggested that this efficacy could also apply to infants and children. Data from the active surveillance networks of pediatric BM and pneumococcal resistance in France suggested that DXM anti-inflammatory effect on antibiotic CSF penetration would not have a significant impact on the bactericidal efficacy if recommended dosages of cefotaxime (300 mg/kg per day) and vancomycin (60 mg/kg per day) were used. DXM could be considered in the early treatment of pneumococcal BM in infants and children in industrialized countries. But there is no proven efficacy of DXM in meningococcal meningitis in infants and children.
Asunto(s)
Corticoesteroides/uso terapéutico , Dexametasona/uso terapéutico , Meningitis Bacterianas/tratamiento farmacológico , Adolescente , Antiinflamatorios/uso terapéutico , Niño , Preescolar , Países Desarrollados , Infecciones por Haemophilus/tratamiento farmacológico , Infecciones por Haemophilus/fisiopatología , Haemophilus influenzae , Humanos , Lactante , Meningitis Bacterianas/fisiopatologíaRESUMEN
BACKGROUND: The implementation of Haemophilus influenzae b (Hib) vaccination program in France in 1993 resulted in a rapid and dramatic decrease of the Hib meningitis incidence in children. The aim of our study was to describe the residual Haemophilus influenzae (Hi) meningitis in the French paediatric population between 2001 and 2006. METHODS: The French Paediatric Infectious Diseases Group set up an active surveillance network to analyze the clinical and biological features of bacterial meningitis. We used these data to retrospectively study the risk factors, signs and symptoms, vaccination status, cerebrospinal fluid analysis, treatment and case fatality rate of Hi meningitis. RESULTS: Among the 2539 cases of bacterial meningitis reported in France between 2001 and 2006, 69 (2.7 %) were due to Hi. A mean number of 11.5 cases of Hi meningitis was reported annually (minimum 6, maximum 16). Among Hi meningitis cases, 36 strains were of serotype b, 8 were capsulated but not b (6 f, 1 e and 1 unknown serotype), 20 strains were not capsulated, and 5 were non studied. The mean age of the children was 30.3 months (median 13.8 months, range 3.3 months to 14.5 years). 41 % of children with Hib meningitis did not received any anti-Hib vaccine and 41 % did not followed the French recommendations for Hib vaccine. CONCLUSION: Hi meningitis still occurs, and more than half is due to the b serotype. Among Hib cases, 14 % did not recieved any anti-Hib vaccine and 15 % received an incomplete vaccination schedule. Increase of vaccine coverage and use of an earlier booster dose at the age of 12 months could further improve the epidemiology of Hib meningitis. The immunity of children with Hib meningitis should be systematically studied in order to improve the comprehension of the pathophysiology of vaccine failure.
Asunto(s)
Vacunas Bacterianas/administración & dosificación , Meningitis por Haemophilus/epidemiología , Meningitis por Haemophilus/inmunología , Adolescente , Vacunas Bacterianas/uso terapéutico , Niño , Francia/epidemiología , Humanos , Esquemas de Inmunización , Incidencia , Lactante , Recién Nacido , Recien Nacido Prematuro , Recurrencia , Factores de RiesgoRESUMEN
Vestibular syndrome is not frequently described in patients with sickle cell disease. We report the case of a teenager with sickle cell disease who had a vestibular syndrome with vertigo that successfully responded to exchange transfusion. We discuss guidelines and review the literature in view of this case report. Sensorineural disorders should be considered as stroke syndromes. They require urgent treatment consisting of exchange transfusion or maintaining optimal hydration associated with blood withdrawal. Treatment of vestibular syndrome in sickle cell disease is urgent.
Asunto(s)
Anemia de Células Falciformes/complicaciones , Neuronitis Vestibular/terapia , Adolescente , Recambio Total de Sangre , Femenino , Humanos , Vértigo/etiología , Vértigo/terapia , Neuronitis Vestibular/complicacionesRESUMEN
Management of paediatric skeletal infections remains delicate in France due to the absence of general agreement or official recommendations from the French National Societies. However, practices have evolved since 40 years towards simplified and mostly ambulatory treatment modalities. The Paediatric Infectious Diseases Group of the French Society of Paediatrics (GPIP) has elaborated guidelines funded on the joint analysis of bacterial epidemiology, comparison of common antimicrobial spectra, pharmacokinetic and pharmacodynamic parameters and clinical studies. The aim of this article is to review the evolution of therapeutic concepts of treatment of bone and joint infections in paediatrics for 40 years with the aid of main published clinical studies.
Asunto(s)
Antibacterianos/uso terapéutico , Infecciones Bacterianas/tratamiento farmacológico , Enfermedades Óseas Infecciosas/tratamiento farmacológico , Artropatías/microbiología , Artritis Infecciosa/tratamiento farmacológico , Niño , Ensayos Clínicos como Asunto , Humanos , Artropatías/tratamiento farmacológico , Osteomielitis/tratamiento farmacológico , Guías de Práctica Clínica como AsuntoRESUMEN
The empiric choice of initial antibiotherapy in osteoarticular infections in infants and children must take into consideration the actual epidemiology of principal pathogens, their respective antibiotic sensitivity profile, their pharmacokinetic and pharmacodynamic properties and the results of efficacy clinical studies. After a review of recent data concerning these four major points, the Paediatric Infectious Diseases Group of the French Society of Paediatrics (GPIP) has proposed guidelines for initial recommended schemes of antimicrobial therapy in acute and non complicated osteoarticular infections in infants and children.
Asunto(s)
Antibacterianos/uso terapéutico , Infecciones Bacterianas/tratamiento farmacológico , Enfermedades Óseas Infecciosas/tratamiento farmacológico , Artropatías/microbiología , Administración Oral , Combinación Amoxicilina-Clavulanato de Potasio/uso terapéutico , Antibacterianos/farmacocinética , Antibacterianos/farmacología , Bacterias/clasificación , Bacterias/efectos de los fármacos , Niño , Infecciones Comunitarias Adquiridas/tratamiento farmacológico , Infección Hospitalaria/tratamiento farmacológico , Farmacorresistencia Bacteriana , Fluoroquinolonas/uso terapéutico , Humanos , Lactante , Artropatías/tratamiento farmacológico , Kingella kingae/efectos de los fármacos , Resistencia a la Meticilina , Staphylococcus aureus Resistente a Meticilina/efectos de los fármacos , Infecciones por Neisseriaceae/tratamiento farmacológico , Penicilinas/uso terapéutico , Infecciones Neumocócicas/tratamiento farmacológico , Pristinamicina/uso terapéutico , Rifampin/uso terapéutico , Infecciones Estafilocócicas/tratamiento farmacológico , Staphylococcus aureus/efectos de los fármacos , Resultado del TratamientoRESUMEN
Paediatric patients hospitalised with varicella (n = 1575) were reported to a French national network between March 2003 and July 2005. Superinfection was identified in 50.3% of cases, principally of skin and soft-tissue (36.5%). The risk of superinfection increased with fever relapse, use of non-steroidal anti-inflammatory drugs, prolonged fever, an age of 1-5 years, and contamination at the childminder's home. Neurological complications were observed in 7.8% of cases, while pulmonary complications were less frequent (3.1%). Forty-nine patients had sequelae and eight patients died. Surveillance should continue in France with a view to the future implementation of a universal vaccination programme.
Asunto(s)
Varicela/epidemiología , Niño Hospitalizado/estadística & datos numéricos , Enfermedades Cutáneas Bacterianas/epidemiología , Sobreinfección/epidemiología , Corticoesteroides/efectos adversos , Factores de Edad , Varicela/complicaciones , Varicela/inmunología , Preescolar , Femenino , Francia/epidemiología , Encuestas Epidemiológicas , Hospitalización , Humanos , Lactante , Recién Nacido , Masculino , Oportunidad Relativa , Vigilancia de la Población , Factores de Riesgo , Enfermedades Cutáneas Bacterianas/virología , Sobreinfección/microbiologíaRESUMEN
Universal vaccination of infants against pertussis has transformed the epidemiology of the disease. Pertussis has however become frequent, although not often diagnosed, in adolescents and adults and thus contributes to permanent transmission of Bordetella pertussis in France and contamination of young infants at risk of severe disease. Control of transmission of pertussis in France necessitates reinforcement of vaccination with late boosters in adolescents and adults and, in addition, education of physicians to recognize and treat early cases of pertussis, especially in adolescents and adults with a persistent or chronic cough, and to take appropriate prophylactic measures (antibiotics and recall vaccination) of those in contact with confirmed cases. Effective treatment does little to reduce symptoms but it does reduce transmission. Macrolides are the recommended treatment for pertussis.
Asunto(s)
Tos Ferina , Niño , Humanos , Vacuna contra la Tos Ferina , Tos Ferina/complicaciones , Tos Ferina/diagnóstico , Tos Ferina/terapiaRESUMEN
The progress in the knowledge of antibiotic action mechanisms have led to determine phamacodynamic/pharmacokinetic (PK/PD) parameters predictive of antibiotic efficacy in bacterial infections. According to the antibiotic compound, the implicated bacterial specie, the localization of the infection, the severity of the disease, these parameters could vary. The PK/PD parameters described in this paper focus only on blood compartment and S. aureus, (main bacteria implicated in bone and joint tissue infections). All beta-lactamase resistant beta-lactam compounds given by IV route, if they are prescribed at the good dosage and frequency, fulfill these PK/PD parameters. In contrast, by oral route, M penicillins and cefuroxime-axetil should not be considered as acceptable regimens. Only amoxicillin-clavulanate and some first generation cephalosporin compounds fulfill the PK/PD parameters predictive of clinical efficacy if S. aureus strains are methicillin susceptible and dosages of cephalosporins are increased. Clindamycin is a very interesting alternative, if the strains are susceptible to macrolides.
Asunto(s)
Antibacterianos/farmacología , Antibacterianos/farmacocinética , Artritis Infecciosa/tratamiento farmacológico , Osteomielitis/tratamiento farmacológico , Infecciones Estafilocócicas/tratamiento farmacológico , Staphylococcus aureus/efectos de los fármacos , Enfermedad Aguda , Administración Oral , Factores de Edad , Amoxicilina/farmacocinética , Amoxicilina/farmacología , Amoxicilina/uso terapéutico , Antibacterianos/administración & dosificación , Antibacterianos/uso terapéutico , Artritis Infecciosa/microbiología , Cefalosporinas/farmacocinética , Cefalosporinas/farmacología , Cefalosporinas/uso terapéutico , Niño , Clindamicina/farmacocinética , Clindamicina/farmacología , Clindamicina/uso terapéutico , Ensayos Clínicos como Asunto , Farmacorresistencia Bacteriana , Humanos , Lactante , Recién Nacido , Infusiones Intravenosas , Inyecciones Intravenosas , Metaanálisis como Asunto , Meticilina/farmacología , Resistencia a la Meticilina , Pruebas de Sensibilidad Microbiana , Osteomielitis/microbiología , beta-Lactamas/farmacocinética , beta-Lactamas/farmacología , beta-Lactamas/uso terapéuticoRESUMEN
Although rare, osteoarticular infections constitute a diagnostic and therapeutic emergency in infants and children. Their incidence has remained stable in the industrialized countries for 20 years. Their evolution has been transformed with the use of antibiotics, mortality has become exceptional and sequelae became rare. Some paediatric specificities of this type of infection are explained by many physiopathological characteristics: bacteriemic inoculation is predominant and corresponds to a particular microbial etiology, the specific vascular and tissue anatomy explains the propensity of articular extension in young infant and the risk of growth sequelae. A generally healthy and richly vascularized ground allows the diffusion of antibiotics and reduces the therapeutic risk of failure and chronicity. Bacterial virulence factors are known principally from a single but prominent agent, Staphylococcus aureus and explain its prevalence (whatever the age) and the potential risk of evolution towards chronicity and the constitution of bone abscesses in adults.
Asunto(s)
Osteomielitis , Adolescente , Adulto , Factores de Edad , Animales , Antibacterianos/uso terapéutico , Artritis Infecciosa/diagnóstico , Artritis Infecciosa/tratamiento farmacológico , Artritis Infecciosa/epidemiología , Artritis Infecciosa/fisiopatología , Bacteriemia/tratamiento farmacológico , Bacteriemia/epidemiología , Desarrollo Óseo , Niño , Preescolar , Modelos Animales de Enfermedad , Femenino , Humanos , Incidencia , Masculino , Osteoartritis/diagnóstico , Osteomielitis/diagnóstico , Osteomielitis/tratamiento farmacológico , Osteomielitis/epidemiología , Osteomielitis/fisiopatología , Factores de Riesgo , Factores Sexuales , Infecciones Estafilocócicas/tratamiento farmacológico , Infecciones Estafilocócicas/epidemiología , Infecciones Estafilocócicas/microbiología , Infecciones Estafilocócicas/fisiopatología , Staphylococcus aureus/patogenicidad , VirulenciaRESUMEN
OBJECTIVE: The Ile-de-France bronchiolitis network assessment gave us the opportunity to carry out a survey regarding the customary handling of acute bronchiolitis by physicians involved in this network. The aim of this study was to retrieve results relating to season 2003-2004 and to compare them with the September 2000 French consensus conference recommendations. METHODS: The practitioners engaged using a special form subsequently transmitted to network joint committee collected the clinical and therapeutic data of the patients included in the Network. We analysed 342 exploitable forms. RESULTS: Analysis of the physicians medications for patients classified as bronchiolitis showed that their behavior was on the whole keeping with the official recommendations. The nearly systematic prescription of specific respiratory physiotherapy (increase in expiratory flow) satisfies the expectations of the French consensus conference. Likewise, treatments such as bronchodilator or corticoids that are not recommended were prescribed only in approximately 1/4 of cases. Abstention from all medical treatment was found in only 41% of cases classified as bronchiolitis. However, in considering only the first episode of acute bronchiolitis, this rate increased to 54,3%. Short-acting bronchodilator usage may appear legitimate as a therapeutic test of reversibility. In our study, 1/3 of patients with bronchiolitis treated by bronchodilator underwent a second episode and 80% of them were older than 6 months. CONCLUSION: Analysis of the practices of physicians participating in the Bronchiolite Ile-de-France Network proves very positive in light of the comparison with studies prior and subsequent to the consensus conference. In recognition of this, it is necessary to consider the importance of the network's training programs. Beyond the need to go on with the diffusion of the recommendations, it seems desirable to extend them to clinical situations not yet considered, especially recurrent bronchiolitis and infant asthma. Finally, this type of study should be repeated in order to measure the future evolution of medical practices, as well as extended to a larger scope than the Ile-de-France bronchiolitis Network.
Asunto(s)
Bronquiolitis/terapia , Pautas de la Práctica en Medicina/estadística & datos numéricos , Corticoesteroides/uso terapéutico , Antibacterianos/uso terapéutico , Broncodilatadores/uso terapéutico , Preescolar , Redes Comunitarias , Utilización de Medicamentos , Femenino , Francia , Adhesión a Directriz , Humanos , Lactante , Masculino , Guías de Práctica Clínica como Asunto , Terapia Respiratoria , Estudios Retrospectivos , Encuestas y CuestionariosRESUMEN
Since 2004, in France, pertussis booster is recommended in parents of young infants and adults likely to become parents. This recommendation adds to others such as rubella vaccination in unvaccinated or seronegative women and decennial dT-IPV booster. The objective of this study is to evaluate the impact of these recommendations in parents of young infants. Pediatricians had to include parents of infants at the first well-baby visit after birth. Vaccination data were secondary recorded from parent's health record or called upon their memory. Between June and October 2006, 41 pediatricians included parents of 400 infants (median age: 36 days). dT-IPV booster was recorded or recalled in 37.4% within the 10 previous years and 17.7% within the 3 previous years. Among this last group, only 11.8% had received a combination including pertussis. Rubella serology was declared as positive by 94% of the mothers, but the physicians obtained the information of a previous rubella vaccination in only 71.7% of the mothers. Among the 9 seronegative mothers during pregnancy, only 3 were vaccinated in postpartum. Adults' immunization guidelines are not well known and poorly applied in France. The unavailability of monovalent pertussis vaccine reduces the eligible population. Two years after the launch of the pertussis cocoon strategy, the coverage of eligible young parents remains low and many opportunities are too frequently missed on the opportunity of decenial dTPolio booster. Rubella catch up strategy should be improved. Adults' vaccination strategies and guidelines need to be better broadcasted to health care professionals and also families.